- Home
- TNGX vs CCNE Comparison
TNGX vs CCNE Comparison
Compare TNGX & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CCNE
- Stock Information
- Founded
- TNGX 2014
- CCNE 1865
- Country
- TNGX United States
- CCNE United States
- Employees
- TNGX N/A
- CCNE N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CCNE Major Banks
- Sector
- TNGX Health Care
- CCNE Finance
- Exchange
- TNGX Nasdaq
- CCNE Nasdaq
- Market Cap
- TNGX 723.2M
- CCNE 775.5M
- IPO Year
- TNGX N/A
- CCNE N/A
- Fundamental
- Price
- TNGX $7.35
- CCNE $25.42
- Analyst Decision
- TNGX Strong Buy
- CCNE Hold
- Analyst Count
- TNGX 6
- CCNE 1
- Target Price
- TNGX $10.00
- CCNE $29.00
- AVG Volume (30 Days)
- TNGX 1.5M
- CCNE 103.0K
- Earning Date
- TNGX 11-05-2025
- CCNE 10-20-2025
- Dividend Yield
- TNGX N/A
- CCNE 2.83%
- EPS Growth
- TNGX N/A
- CCNE 2.16
- EPS
- TNGX N/A
- CCNE 2.38
- Revenue
- TNGX $24,296,000.00
- CCNE $224,762,000.00
- Revenue This Year
- TNGX $20.42
- CCNE $18.69
- Revenue Next Year
- TNGX N/A
- CCNE $29.21
- P/E Ratio
- TNGX N/A
- CCNE $10.69
- Revenue Growth
- TNGX N/A
- CCNE 4.79
- 52 Week Low
- TNGX $1.03
- CCNE $19.32
- 52 Week High
- TNGX $10.81
- CCNE $29.29
- Technical
- Relative Strength Index (RSI)
- TNGX 60.63
- CCNE 51.75
- Support Level
- TNGX $6.38
- CCNE N/A
- Resistance Level
- TNGX $6.90
- CCNE $26.35
- Average True Range (ATR)
- TNGX 0.44
- CCNE 0.42
- MACD
- TNGX 0.00
- CCNE -1.11
- Stochastic Oscillator
- TNGX 94.14
- CCNE 94.32
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CCNE CNB Financial Corporation
CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.